Press release
Cystinuria Pipeline 2025: Innovative Clinical Progress by 5+ Global Leaders - DelveInsight | Highlighting Revive Therapeutics, Otsuka Pharmaceutical, Eloxx Pharmaceuticals, Travere Therapeutics, Advic
Cystinuria Pipeline 2025
As Cystinuria increasingly impacts populations worldwide and is linked to comorbidities such as diabetes, cardiovascular disease, and certain cancers, there is a rising need for safer and more effective treatment options. DelveInsight reports that the Cystinuria pipeline includes over 5 pharmaceutical and biotech companies actively developing more than 5 therapeutic candidates for the condition. These candidates are at various stages of clinical and preclinical development, reflecting significant innovation and dedication to addressing this important health challenge.
DelveInsight's "Cystinuria Pipeline Insight 2025" offers a comprehensive strategic analysis of the R&D landscape, including clinical trial progress, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives. The report serves as a vital resource for researchers, healthcare investors, and decision-makers seeking insights into the evolving Cystinuria therapeutics market and the breakthroughs shaping its future.
Explore the Cutting-Edge Landscape of Cystinuria Drug Development [https://www.delveinsight.com/report-store/cystinuria-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Key Takeaways from the Cystinuria Pipeline Report
*
DelveInsight's Cystinuria pipeline report highlights an active therapeutic landscape with over 5 companies developing more than 5 pipeline candidates for Cystinuria treatment.
*
ADV7103 is currently being assessed in the Phase 2/3 CORAL-1 trial, which is enrolling Cystinuria patients across sites in France and Belgium, with primary study completion anticipated in May 2025. In May 2024, the FDA approved tiopronin delayed-release tablets for patients aged 9 years and older who do not respond to standard therapies.
*
Cycle Pharmaceuticals, in collaboration with Torrent Pharma Inc., launched VENXXIVA Trademark (tiopronin) delayed-release tablets in the U.S. in March 2025. This formulation offers flexible dosing and is supported by patient assistance programs under Cycle Vita Trademark . Additionally, in March 2024, ADV7103 received Orphan Drug Designation from the FDA, incentivizing the development of treatments for rare diseases by providing benefits such as market exclusivity upon approval.
*
Key Cystinuria players including Revive Therapeutics, Otsuka Pharmaceutical, Eloxx Pharmaceuticals, Travere Therapeutics, Advicenne, and others, are actively exploring new therapies to enhance the Cystinuria treatment landscape. Promising pipeline candidates include Bucillamine and several others.
Cystinuria Overview:
Cystinuria is a hereditary metabolic disorder in which the kidneys excrete excessive amounts of cystine and related amino acids-lysine, arginine, and ornithine-into the urine. Since cystine has low solubility, it can form crystals or kidney stones, although not all individuals with the condition develop stones. The disorder results from mutations in the SLC3A1 or SLC7A9 genes, which impair normal amino acid transport in the kidneys. It is inherited in an autosomal recessive manner, requiring two defective gene copies for symptoms to manifest. Carriers typically remain asymptomatic but may have slightly elevated cystine levels in their urine.
Download the Cystinuria sample report to know in detail about the Cystinuria treatment market @ https://www.delveinsight.com/sample-request/cystinuria-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Cystinuria Pipeline Analysis
The Cystinuria pipeline insights report 2025, provides insights into:
*
Provides comprehensive insights into key companies developing therapies in the Cystinuria Market.
*
Categorizes Cystinuria therapeutic companies by development stage: early, mid, and late-stage.
*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
*
Reviews emerging Cystinuria drugs under development based on:
*
Stage of development
*
Cystinuria Route of administration
*
Target receptor
*
Monotherapy vs. combination therapy
*
Cystinuria Mechanism of action
*
Molecular type
*
Offers detailed analysis of:
*
Company-to-company and company-academia collaborations
*
Cystinuria Licensing agreements
*
Funding and investment activities supporting future Cystinuria market advancement.
Unlock key insights into emerging Cystinuria therapies and market strategies here: https://www.delveinsight.com/report-store/cystinuria-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Cystinuria Emerging Drugs
Bucillamine: Revive Therapeutics
Bucillamine, a cysteine-derived medication long used in Japan and South Korea for rheumatoid arthritis, is now being evaluated in Phase 2 trials for cystinuria. The drug features two thiol groups and has demonstrated greater efficacy than NAC in replenishing glutathione levels, highlighting its potential to protect against lung damage during infections such as influenza.
Cystinuria Pipeline Therapeutic Assessment
Cystinuria Assessment by Product Type
- Mono
- Combination
- Mono/Combination
Cystinuria By Stage
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Cystinuria Assessment by Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Cystinuria Assessment by Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Download sample pages to get an in-depth assessment of the emerging Cystinuria therapies and key Cystinuria companies [https://www.delveinsight.com/sample-request/cystinuria-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Contents
1. Report Introduction
2. Executive Summary
3. Cystinuria Current Treatment Patterns
5. Cystinuria - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
5. Cystinuria Late-Stage Products (Phase-III)
7. Cystinuria Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Cystinuria Discontinued Products
13. Cystinuria Product Profiles
15. Cystinuria Key Companies
15. Cystinuria Key Products
15. Dormant and Discontinued Products
17. Cystinuria Unmet Needs
18. Cystinuria Future Perspectives
19. Cystinuria Analyst Review
20. Appendix
21. Report Methodology
Request the sample PDF to get detailed insights about the Cystinuria pipeline reports offerings [https://www.delveinsight.com/report-store/cystinuria-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cystinuria-pipeline-2025-innovative-clinical-progress-by-5-global-leaders-delveinsight-highlighting-revive-therapeutics-otsuka-pharmaceutical-eloxx-pharmaceuticals-travere-therapeutics-advic]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cystinuria Pipeline 2025: Innovative Clinical Progress by 5+ Global Leaders - DelveInsight | Highlighting Revive Therapeutics, Otsuka Pharmaceutical, Eloxx Pharmaceuticals, Travere Therapeutics, Advic here
News-ID: 4198459 • Views: …
More Releases from ABNewswire
Leber's Hereditary Optic Neuropathy (LHON) Pipeline 2025: Pioneering Clinical De …
DelveInsight's, "Leber's Hereditary Optic Neuropathy - Pipeline Insight, 2025," report provides comprehensive insights about 6+ companies and 7+ pipeline drugs in Leber's Hereditary Optic Neuropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
As Leber's hereditary optic neuropathy becomes…
Sanfilippo Syndrome Pipeline 2025: Pioneering Clinical Developments by 8+ Global …
DelveInsight's, "Sanfilippo Syndrome - Pipeline Insight, 2025" report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Sanfilippo Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
With Sanfilippo syndrome becoming increasingly prevalent worldwide and contributing to…
Down Syndrome Market: Epidemiology, Therapies, Companies, DelveInsight | AC Immu …
The Down Syndrome market size in 2023 was approximately USD 241 million in the United States.
Emerging therapies for Down Syndrome, including AEF0217, ACI-24.060, and others, are anticipated to drive growth in the Down Syndrome market in the coming years.
DelveInsight has released a new report titled "Down Syndrome - Market Insights, Epidemiology, and Market Forecast-2034," offering a comprehensive analysis of Down Syndrome, historical and projected epidemiology, and market trends across the…
Pompe Disease Market: Epidemiology, Therapies, Companies, DelveInsight | Featuri …
The United States represents the largest share of the Pompe disease treatment market, accounting for a significant proportion compared to the EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
Emerging therapies for Pompe Disease, including MYOZYME (alglucosidase alfa), LUMIZYME, AAV2/8-LSPhGAA, Avalglucosidase alfa, and others, are anticipated to drive growth in the Pompe Disease market in the coming years.
DelveInsight has published a comprehensive report titled "Pompe Disease - Market Insights,…
More Releases for Cystinuria
Cystinuria Market to Reach USD 2.5 Billion by 2034
Cystinuria is a rare inherited metabolic disorder characterized by defective renal transport of certain amino acids, particularly cystine, which leads to the formation of recurrent kidney stones. This autosomal recessive condition is caused by mutations in the SLC3A1 and SLC7A9 genes and affects approximately 1 in 7,000 to 1 in 10,000 individuals worldwide.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71685
Although not life-threatening when managed effectively, cystinuria poses a…
Future Scope of Cystinuria Treatment Market Expects to See Significant Growth Du …
"
The Cystinuria Treatment Market addresses a rare inherited metabolic disorder characterized by the excessive excretion of cystine, an amino acid, in the urine. This condition leads to the formation of cystine stones in the kidneys, ureters, and bladder, causing significant pain, urinary tract infections, and potentially kidney damage. The market encompasses various treatment options aimed at managing the condition, including medications to dissolve or prevent stone formation, surgical procedures to…
Cystinuria Pipeline 2025: Groundbreaking Clinical Advancements by 5+ Global Lead …
With Cystinuria reaching epidemic proportions globally and contributing significantly to comorbid conditions such as diabetes, cardiovascular disease, and certain cancers, there is a growing demand for safer, more effective treatment options. According to DelveInsight, the Cystinuria pipeline comprises 5+ pharmaceutical and biotech companies actively developing 5+ therapeutic candidates targeting Cystinuria. These therapies span various stages of clinical and non-clinical development, underscoring the intense innovation and commitment to addressing one of…
Cystinuria Treatment Market Growth Trends, Regional Breakdown, Segmentation, Res …
The Cystinuria Treatment Market study by DataM Intelligence offer an in-depth analysis of the market, presenting insightful observations, statistics, historical data, and industry-validated market insights. The report delves into the competitive positioning of key companies, examining factors such as product offerings, pricing strategies, financial health, product portfolios, growth initiatives, and geographical reach.
Get a Free Sample PDF - https://datamintelligence.com/download-sample/cystinuria-treatment-market
What is the projected growth rate (CAGR) of the Global Cystinuria Treatment market…
Cystinuria Market Report: Epidemiology, Trends and Forecast to (2023-2033)
IMARC Group has recently released a report titled "Cystinuria Market: Analysis of Epidemiology, Industry Trends, Size, Share, and Future Forecast (2023-2033)" that presents a comprehensive assessment of the cystinuria market. The report provides an extensive overview of the latest market trends, growth prospects, investment opportunities, and industry outlook, as well as an in-depth analysis of the disease landscape, market size, and growth trends. Furthermore, the report offers an analysis of…
Cystinuria Treatment Market is expected to grow at a CAGR of 6.00% during the fo …
Data Bridge Market Research analyzes that the Cystinuria Treatment Market will grow at a CAGR of roughly 6.00% during the forecast period 2021-2028. Growing demand for targeted therapies, increased research and development activities for the development of new drugs and therapies, and increased expenditures for the development of healthcare infrastructure are the major factors attributable to growth of the cystinuria treatment market.
Cystinuria is a rare inherited condition that causes…
